ArticleCellular oncology (Dordrecht, Netherlands)2015
Expression of the microRNA regulators Drosha, Dicer and Ago2 in non-small cell lung carcinomas.
Article in Cellular oncology (Dordrecht, Netherlands), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 34 citations in OpenAlex.
- MicroRNAs in endometriosis: bioinformatics resources, machine learning strategies, and multi-omics perspectives.Journal of translational medicine · 2026Review
- Targeting Oncogenic miRNAs in NSCLC: Therapeutic Strategies and Emerging Approaches.Cancer management and research · 2026Review
- Variant Analysis of miRNA Regulatory Genes in 35 Sporadic Lung Carcinoma Tumors.Doklady. Biochemistry and biophysics · 2023Article
- Research progress on the therapeutic effect and mechanism of metformin for lung cancer (Review).Oncology reports · 2023Review
- HIF-1α-mediated augmentation of miRNA-18b-5p facilitates proliferation and metastasis in osteosarcoma through attenuation PHF2.Scientific reports · 2022Article
- Mechanism underlying the effect of Liujunzi decoction on advanced-stage non-small cell lung cancer in patients after first-line chemotherapy.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2022Article
- Methylation ofCancers · 2021Article
- Impaired AGO2/miR-185-3p/NRP1 axis promotes colorectal cancer metastasis.Cell death & disease · 2021Article
- Dicing the Disease with Dicer: The Implications of Dicer Ribonuclease in Human Pathologies.International journal of molecular sciences · 2020Review
- Plasma and Tissue Specific miRNA Expression Pattern and Functional Analysis Associated to Colorectal Cancer Patients.Cancers · 2020Article
- Accumulation of AGO2 Facilitates Tumorigenesis of Human Hepatocellular Carcinoma.BioMed research international · 2020Article
- Quantifying Argonaute 2 (Ago2) expression to stratify breast cancer.BMC cancer · 2019Article
- The impact of variations in transcription of DICER and AGO2 on exacerbation of childhood B-cell lineage acute lymphoblastic leukaemia.International journal of experimental pathology · 2019Article
- Quantifying Tip60 (Kat5) stratifies breast cancer.Scientific reports · 2019Article
- Premature senescence activation in DLD-1 colorectal cancer cells through adjuvant therapy to induce a miRNA profile modulating cellular death.Experimental and therapeutic medicine · 2018Article
- Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection.Cellular oncology (Dordrecht, Netherlands) · 2017Article
- The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells.Cellular oncology (Dordrecht, Netherlands) · 2016Article
- Estrogen receptor expression and gene promoter methylation in non-small cell lung cancer - a short report.Cellular oncology (Dordrecht, Netherlands) · 2016Article
- Nitric oxide increases the migratory activity of non-small cell lung cancer cells via AKT-mediated integrin αv and β1 upregulation.Cellular oncology (Dordrecht, Netherlands) · 2016Article
- A network including PU.1, Vav1 and miR-142-3p sustains ATRA-induced differentiation of acute promyelocytic leukemia cells - a short report.Cellular oncology (Dordrecht, Netherlands) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMicroRNAs are evolutionarily conserved non-coding components of the transcriptome that can post-transcriptionally control gene expression. Altered microRNA expression has been found to be a common feature of several cancers, including lung carcinomas. The biogenesis and maturation of microRNAs is known to be mediated by the ribonucleases Drosha, Dicer and Ago2. The purpose of the present study was to investigate the expression and distribution of Drosha, Dicer and Ago2 in human non-small cell lung carcinomas (NSCLC) and to relate the respective expression patterns to clinocopatholical features.
methodsWe used five human NSCLC-derived cell lines and primary formalin-fixed paraffin-embedded tissue samples from 83 NSCLC patients. Drosha, Dicer and Ago2 mRNA and protein expression levels, and their sub-cellular distributions, were assessed using RT-PCR, Western blotting, immunofluorescence and immunohistochemistry, respectively.
resultsWe found that Drosha, Dicer and Ago2 were expressed in all the cell lines and primary neoplastic and non-neoplastic tissue samples tested. The intensity of the immunohistochemical staining was found to be significantly lower in stage I tumors compared to normal lung tissues. Dicer expression was found to be significantly higher in stage II compared to stage I tumors, and in stage III compared to stage II and stage I tumors.
conclusionsOur results point at a role of Drosha, Dicer and Ago2 in the development of NSCLC and suggest that Dicer may be implicated in the progression of these tumors to advanced stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.